Anna P. Petrashen

Anna P. Petrashen

Auto-generated profile, based on publicly available information

Anna P. Petrashen

Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Autophagy
Verified
Journal Article
Open access
NSNicole E. Seah
Nicole E. Seah
CFC. Daniel de Magalhaes Filho
C. Daniel de Magalhaes Filho
APAnna P. Petrashen
Anna P. Petrashen
HHHope R. Henderson
Hope R. Henderson
JLJade Laguer
Jade Laguer
LLLouis R. Lapierre
Louis R. Lapierre
Autophagy-dependent longevity models in C. elegans display altered lipid storage profiles, but the contribution of lipid distribution to life-span extension is not fully understood. Here we report that lipoprotein production, autophagy and lysosomal lipolysis are linked to modulate life span in a conserved fashion. We find that overexpression of the yolk lipoprotein VIT/vitellogenin reduces the life span of long-lived animals by impairing the induction of autophagy-related and lysosomal genes necessary for longevity. Accordingly, reducing vitellogenesis increases life span via induction of autophagy and lysosomal lipolysis. Life-span extension due to reduced vitellogenesis or enhanced lysosomal lipolysis requires nuclear hormone receptors (NHRs) NHR-49 and NHR-80, highlighting novel roles for these NHRs in lysosomal lipid signaling. In dietary-restricted worms and mice, expression of VIT and hepatic APOB (apolipoprotein B), respectively, are significantly reduced, suggesting a conserved longevity mechanism. Altogether, our study demonstrates that lipoprotein biogenesis is an important mechanism that modulates aging by impairing autophagy and lysosomal lipolysis.

4 June 2015 in Journal of Proteome Research
Verified
Journal Article
Closed access
YHYnes A. Helou
Ynes A. Helou
APAnna P. Petrashen
Anna P. Petrashen
ASArthur Salomon
Arthur Salomon

23 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJosé P. Castro
José P. Castro
ASAnastasia V. Shindyapina
Anastasia V. Shindyapina
ABAlessandro Barbieri
Alessandro Barbieri
KYKejun Ying
Kejun Ying
OSOlga S. Strelkova
Olga S. Strelkova
VGVadim N Gladyshev
Vadim N Gladyshev
While cancer is an age-related disease, many cancer studies utilize younger animal models. Here, we uncover how a cancer, B-cell lymphoma, develops as a consequence of a naturally aged system. We show that this malignancy is associated with increased cell size, splenomegaly, and a newly discovered age-associated clonal B-cell (ACBC) population. Driven by exogenous c-Myc activation, hypermethylated promoters and somatic mutations, ACBC cells clonally expand independent of germinal centers (IgM+) and show increased biological age and hypomethylation in partially methylated domains related to mitotic solo-CpGs. Epigenetic changes in transformed mouse B cells are enriched for changes observed in human B-cell lymphomas. Mechanistically, the data suggest that cancerous ACBC cells originate from age-associated B cells, in part involving CD22 protein signaling fostered by the aging microenvironment. Transplantation assays demonstrate that ACBC evolve to become self-sufficient and support malignancy when transferred into young recipients. Inhibition of mTOR or c-Myc in old mice attenuates premalignant changes in B cells during aging and emerges as a therapeutic strategy to delay the onset of age-related lymphoma. Together, we show how aging contributes to B-cell lymphoma through a previously unrecognized mechanism involving cell-intrinsic changes and the aged microenvironment, characterize a model that captures the origin and progression of spontaneous cancer during aging and identify candidate interventions against age-associated lymphoma.